Sanofi

Sanofi-aventis

Philip Janiak

Dieter Kadereit

Andreas Evers

Elisabetta Bianchi

Gilbert Lassalle

Jean-Michel Altenburger

Jean Claude Vernieres

Bruno Poirier

Paulus Wohlfart

Fabrice Viviani

Matthias Schaefer

Jean-Marc Herbert

Nis Halland

Nicolas Baurin

Thomas Huebschle

Han Li

Gilbert Marciniak

Valérie Fossey

Alessia Santoprete

Dorothea Kominos

Jean-Claude Vernieres

Alla Pritsker

Magali Mathieu

Jean-Francois Nave

Ralf Elvert

Alexey Rak

Frédéric Petit

Frederic Petit

Francis Duffieux

Mohammed Bensaid

Ziyu Li

Ashfaq Parkar

Philippe Beauverger

Sabine Gratzer

Véronique Briand

Cyril Daveu

Christopher Ryan Morgan

Patrick Grailhe

Marie-Laure Ozoux

Daniela Roversi

Laetitia Ledein

Laurence Lucats

Martina Tripepi

Jean-François Nave

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

A subject-matter of the present invention is the use of compounds of formula (I) in the base, hydrate or solvate form or in the form of their mixtures, as medicaments or for the preparation of medicaments intended for the treatment of at least one cardiovascular disease and/or to prevent the appearance of at least one cardiovascular disease.

Therapeutic applications in the cardiovascular field of quinazolinedione derivatives

The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.

5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists

5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists

This invention relates to use of a pyrazole-derived compound that is an antagonist of cannabinoid CBreceptors, alone or in combination with another active ingredient, for preparing medicinal products that are of use in the prevention and treatment of kidney diseases.

Use of a pyrazole derivative for preparing medicines useful for treating renal diseases

Growing community of inventors

Gif sur Yvette, France

Philip Janiak